Alpha Beta Therapeutics

Alpha Beta Therapeutics is a private oncology biotech developing fully humanized antibody therapeutics designed to redirect tumor-associated macrophages to kill cancer cells. The company's approach focuses on aggressive, treatment-resistant tumors expressing integrin alpha-V/beta-3 and aims to trigger macrophage-mediated antibody-dependent cellular cytotoxicity rather than relying primarily on natural killer cell activity. Its lead disclosed program appears to be ABT101, a preclinical anti-Integrin alpha-V/beta-3 monoclonal antibody originating from work associated with UC San Diego. Public information suggests the company is at an early stage with a narrow pipeline centered on antibody-based immuno-oncology.